Clinical studies have shown that concurrent mutations in KEAP1, SMARCA4, and CDKN2A are strongly associated with poor therapeutic responses to KRASG12C inhibitor monotherapy in patients with advanced NSCLC (102). Here, CDKN2A is linked to non-small cell lung carcinoma.